@article{10.37349/etat.2025.1002305,
abstract = {The combination of lenvatinib and pembrolizumab (Len + Pembro) demonstrated significant efficacy in the phase 3 CLEAR study for metastatic renal cell carcinoma (RCC). However, poor-risk patients represented only a small proportion of the trial population. This multicenter retrospective cohort study assessed the real-world efficacy and safety of Len + Pembro in patients with clear-cell metastatic RCC and intermediate or poor International Metastatic RCC Database Consortium risk. Outcomes included objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and safety. Sixty patients were analyzed, with a median age of 56 years. Poor risk was identified in 53% of patients, and 90% had metastases to ≥ 2 organs. ORR was 48.33%, disease control rate was 86.7%, and median PFS was 19.0 months. Grade ≥ 3 adverse events occurred in 25% of patients, with 33.3% requiring lenvatinib dose reductions. Lenvatinib plus pembrolizumab demonstrated robust efficacy and a manageable safety profile in a real-world population with advanced disease and poor-risk features, consistent with outcomes reported in clinical trials.},
author = {Tsimafeyeu, Ilya and Sultanbaev, Alexander and Dubovichenko, Daria and Murzalina, Makhabbat and Volkov, Alexander and Orlova, Rashida and Utyashev, Igor and Malina, Georgy and Gluzman, Mark},
doi = {10.37349/etat.2025.1002305},
journal = {Exploration of Targeted Anti-tumor Therapy},
elocation-id = {1002305},
title = {Real-world outcomes of lenvatinib plus pembrolizumab in intermediate- and poor-risk metastatic renal cell carcinoma},
url = {https://www.explorationpub.com/Journals/etat/Article/1002305},
volume = {6},
year = {2025}
}